The Signal
$LPTH has crossed from tariff-protected narrative into supply-chain fortress. Molded BlackDiamond germanium-alternative optics now scale to 200k+ drones/year where diamond-turn legacy cannot. The Jan 1, 2027 germanium waiver cliff + 100% tariffs on thermal-imaging drones create two hard federal deadlines. $IOVA's Amtagvi revenue inflection is now binding on manufacturing capacity—Wells Fargo $14 PT signals acquisition trigger inside 18 months if solid tumor TIL data clears. Both plays are chokepoint M&A setups independent of macro unwind.
IMPORTANT
Two structural supply-chain moats (defense optics + biotech manufacturing bottleneck) now being actively mapped by institutional research.
What's Moving
- $LPTH — $111M backlog vs. $37.4M YoY growth validates procurement lock. Molded tooling processes 200k+ drones/year; diamond-turn maxes at one-off production. Russell passive inclusion + BlackRock 6.5% locks float. Office of Strategic Capital funding conversations underway per CEO. (via @optimusdelta, @bussinbiotech)
- $IOVA — Amtagvi acceleration outpacing manufacturing capacity. Wells Fargo $14 PT (>2x current). TIL solid tumor indication clears inside 18 months = acquisition trigger certain. Long spot + 2027 $5 calls positioned for catalyst. (via @crypto_condom)
- $UMAC — $8M capital commitment into LightPath optics Sept 2025. Drone OEM with leveraged exposure into counter-UAS without direct optics bet. Piper same-day OW initiation signals institutional dot-joining. (via @optimusdelta)
- $ONDS — Three of four backlog segments ($658M of $757M) EO/IR bearing. Counter-drone platform flagged in earnings: passive RF + EO/IR sensor fusion. Someone supplies all that thermal. Beneficiary play if $LPTH entry missed.
Crosscurrents
- Valuation Gravity — $LPTH and $IOVA trading on catalysts + narrative, not earnings multiples. Macro unwind (carry trade, AI leverage unwound, interest-rate vol rising) could compress multiples faster than fundamentals can justify. Foreigners max-leveraged long AI stocks. (via @globalflows)
- Manufacturing Reality Check — $IOVA's binding constraint is production, not demand or approval. Revenue acceleration alone doesn't guarantee acquisition at premium if capex requirements balloon. Solid tumor data is binary—no gray area on risk. (via @crypto_condom)
Tradecraft
BULL
Defense sole-source + federal deadlines + biotech manufacturing scarcity = three independent catalysts firing. Russell inclusion locks $LPTH float; procurement backlog validates demand before tariff wall took effect.
BEAR
Macro positioning fragile: carry trade unwound, AI leverage still embedded, interest rate vol rising. Any equity pullback could trigger margin calls before catalysts mature.
WATCH
$LPTH: Office of Strategic Capital funding announcement (capacity/money confirm). $IOVA: Solid tumor TIL data readout (18-month window). $UMAC: Q3 guidance on drone OEM bookings.
Desk Notes
- @optimusdelta — Two-position conviction play: $LPTH + $UMAC as cleanest expressions of US drone super-cycle infrastructure layer. Not trading Amba anymore; deployed profits into LPTH on tariff enforcement thesis.
- @crypto_condom — Surgical oncology practitioner. TIL therapy = first meaningful ORR/regression potential in metastatic NSCLC. $IOVA risk is manufacturing, not biology. Holding spot + 2027 calls.
- @globalflows — Macro positioning is fragile. Carry unwind, interest-rate vol, AI leverage uncut. Equity pullback risk is real; hedging accordingly. Watching Japan MoF deficit/short-end rate dynamics.
- @bussinbiotech — $LPTH optics in 7/10 US drones. White House national security doc flags BlackDiamond-class materials as critical. NGSRI job posting (NPI engineer, Visimid/Plano) signals low-rate production ramp confidence.